Though Boston Scientific brought in $4.66 billion in revenue for the first quarter of 2025, up 20.9% year over year, the medical devicemaker is bracing for a potential $200 million hit in the second half of the year stemming from recently imposed tariffs.
Here are three notes:
- The company exceeded earnings across the board in the last quarter, 11.5% above analyst estimates, according to an April 24 earnings report.
- Despite strong financial performance, CFO Daniel Brennan said the tariffs pose a cost challenge going forward. He said they will not trigger a shift in manufacturing locations, explaining that the company plans to absorb the impact through a combination of stronger sales and reduced discretionary spending.
- CEO Mike Mahoney echoed the sentiment, adding that Boston Scientific remains focused on its “category leadership strategy,” including new product launches and continued clinical investment.
“We remain excited about our near and long-term growth catalysts, which we believe will enable us to deliver consistent differentiated performance this year and well beyond,” he said.
